NCT07513311 A Nurse-Led, Coping and Supportive Intervention for Patients With Triple-Negative Breast Cancer
| NCT ID | NCT07513311 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Massachusetts General Hospital |
| Condition | Triple Negative Breast Cancer (TNBC) |
| Study Type | INTERVENTIONAL |
| Enrollment | 75 participants |
| Start Date | 2026-07-07 |
| Primary Completion | 2028-07-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 75 participants in total. It began in 2026-07-07 with a primary completion date of 2028-07-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to explore the feasibility and acceptability of a nurse-led, coping, and supportive care intervention for patients with triple-negative breast cancer. The intervention aims to improve psychosocial outcomes in patients with triple-negative breast cancer (e.g., quality of life (QOL), anxiety, fear of cancer recurrence (FCR)).
Eligibility Criteria
Inclusion Criteria: * Diagnosis of stage 1-3 triple-negative breast cancer * Age ≥ to 18 years * Between one and 12 months post curative therapy * Reporting distress at least 4/10 on a one-item screener * Ability to read and respond in English or Spanish Exclusion Criteria: * Patients with stage 4 cancer * Patients with impaired cognition or serious mental illness that would preclude participation in study procedures
Contact & Investigator
Kathryn E Post, PhD, RN, ANP-BC
PRINCIPAL INVESTIGATOR
Massachusetts General Hospital
Frequently Asked Questions
Who can join the NCT07513311 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Triple Negative Breast Cancer (TNBC). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07513311 currently recruiting?
Yes, NCT07513311 is actively recruiting participants. Contact the research team at kepost@mgh.harvard.edu for enrollment information.
Where is the NCT07513311 trial being conducted?
This trial is being conducted at Boston, United States.
Who is sponsoring the NCT07513311 clinical trial?
NCT07513311 is sponsored by Massachusetts General Hospital. The principal investigator is Kathryn E Post, PhD, RN, ANP-BC at Massachusetts General Hospital. The trial plans to enroll 75 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.